Rapid conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009

Online Available Authors: Geller, J. C.; Egstrup, K.; Kulakowski, P.; Rosenqvist, M.; Jansson, M. A.; Berggren, A.; Edvardsson, N.; Sager, P.; Crijns, H. J.; Publishing Info: J Clin Pharmacol , 49(3), 312-322. Year: 2009

Abstract: This randomized, double-blind trial compared cardioversion rates between AZD7009 infusion (15-minute 3.25 mg/min, 15-minute 4.4 mg/min, or 30-minute 3.25 mg/min) and placebo infusion (15 or 30 minutes) in patients with atrial fibrillation (AF) scheduled for DC cardioversion. One hundred sixty-eight patients were randomized, 167 received study treatment, and 159 were included in perprotocol analyses. The mean duration of current AF episode was 47 days (range, 0.8-92). In the AZD7009 30-minute 3.25 mg/min group, 21 of 42 patients converted within 90 minutes, compared with 7 of 39, 7 of 36, and 0 of 42 patients in the 15-minute 3.25 mg/min, 15-minute 4.4 mg/min, and combined placebo groups, respectively. Patients not converted within 90 minutes underwent DC cardioversion. In patients with AF episodes